<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Right heart failure: Causes and management
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Right heart failure: Causes and management
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Right heart failure: Causes and management
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Author:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Barry A Borlaug, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Donna Mancini, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Todd F Dardas, MD, MS
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Nov 03, 2022.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H117957117">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Right heart failure (RHF) is a clinical syndrome in which symptoms and signs are caused by dysfunction of the right heart structures (predominantly the right ventricle [RV], but also the tricuspid valve apparatus and right atrium) or impaired vena cava flow, resulting in impaired ability of the right heart to perfuse the lungs at normal central venous pressures [
         <a href="#rid1">
          1-3
         </a>
         ]. The terms RHF and RV dysfunction are not synonymous, as some patients have asymptomatic RV dysfunction, and not all RHF is caused by RV dysfunction. Many specific cardiovascular disorders lead to the clinical syndrome of RHF through a variety of mechanisms.
        </p>
        <p>
         This topic will address evaluation of the cause and management of RHF. The clinical manifestations, diagnosis, and pathophysiology of RHF are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/126513.html" rel="external">
          "Right heart failure: Clinical manifestations and diagnosis"
         </a>
         .)
        </p>
        <p>
         Other aspects of HF are discussed separately including the diagnosis and evaluation of HF, management of HF with reduced ejection fraction, and management of HF with preserved ejection fraction. (See
         <a class="medical medical_review" href="/z/d/html/3510.html" rel="external">
          "Heart failure: Clinical manifestations and diagnosis in adults"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/3485.html" rel="external">
          "Determining the etiology and severity of heart failure or cardiomyopathy"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/121085.html" rel="external">
          "Overview of the management of heart failure with reduced ejection fraction in adults"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/3504.html" rel="external">
          "Heart failure with preserved ejection fraction: Clinical manifestations and diagnosis"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/3461.html" rel="external">
          "Treatment and prognosis of heart failure with preserved ejection fraction"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H991216907">
         <span class="h1">
          EVALUATING THE CAUSE OF RIGHT HEART FAILURE
         </span>
        </p>
        <p class="headingAnchor" id="H429321348">
         <span class="h2">
          General approach
         </span>
         <span class="headingEndMark">
          —
         </span>
         The process of evaluating the cause of RHF overlaps the process of diagnosing RHF, starting with assessment of clinical manifestations and diagnostic testing that not only supports diagnosis of RHF but also provides information about the cause of RHF, with further evaluation as needed to identify the cause. (See
         <a class="medical medical_review" href="/z/d/html/126513.html" rel="external">
          "Right heart failure: Clinical manifestations and diagnosis", section on 'Clinical manifestations'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/126513.html" rel="external">
          "Right heart failure: Clinical manifestations and diagnosis", section on 'Diagnosis'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H4124247174">
         <span class="h2">
          Evaluation based upon presentation
         </span>
         <span class="headingEndMark">
          —
         </span>
         Since patients with RHF commonly have an antecedent condition causing or predisposing to RHF, the patient's clinical presentation (eg, medical history, symptoms, signs, initial tests, and echocardiography) often strongly suggests the cause of RHF. Evaluation of each of the following conditions is discussed further in the linked topics. (See
         <a class="medical medical_review" href="/z/d/html/126513.html" rel="external">
          "Right heart failure: Clinical manifestations and diagnosis", section on 'Common clinical settings'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3469226349">
         <span class="h3">
          Acute right heart failure
         </span>
         <span class="headingEndMark">
          —
         </span>
         Causes of acute RHF include the following conditions. These are generally distinguished by clinical presentation and initial testing, including echocardiography, with further testing such as cardiac catheterization in selected patients.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Causes of acute dyspnea and pulmonary hypertension (PH).
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Pulmonary embolism commonly presents with acute onset dyspnea, pleuritic chest pain, and cough, but symptoms may be nonspecific or absent. The diagnostic approach varies depending on the patient's hemodynamic stability and pretest probability. (See
         <a class="medical medical_review" href="/z/d/html/8261.html" rel="external">
          "Clinical presentation, evaluation, and diagnosis of the nonpregnant adult with suspected acute pulmonary embolism"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/8253.html" rel="external">
          "Epidemiology and pathogenesis of acute pulmonary embolism in adults"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Adult respiratory distress syndrome (ARDS) [
         <a href="#rid4">
          4
         </a>
         ] typically presents with progressive dyspnea, increasing oxygen requirement, and alveolar infiltrates on chest imaging within several hours to days following an inciting event  (
         <a class="graphic graphic_table graphicRef58759" href="/z/d/graphic/58759.html" rel="external">
          table 1
         </a>
         ). ARDS is diagnosed after cardiogenic pulmonary edema and other causes of acute hypoxemic respiratory failure and bilateral infiltrates have been excluded. (See
         <a class="medical medical_review" href="/z/d/html/1637.html" rel="external">
          "Acute respiratory distress syndrome: Clinical features, diagnosis, and complications in adults", section on 'Diagnosis'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Causes of new onset dyspnea with primary RV dysfunction – While RV systolic dysfunction is seen with most patients with RHF, in these patients, RV systolic dysfunction is a dominant feature.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         RV myocardial infarction (RVMI) presents with acute symptoms of MI including chest pain, nausea, vomiting, and diaphoresis. The presentation of MI with hypotension, jugular venous distention, and clear lung fields is specific but not sensitive for RVMI. RVMI should be carefully distinguished from acute pulmonary embolus and other causes of similar clinical features. Electrocardiographic findings and troponin levels may suggest RVMI, and echocardiography is generally helpful in identifying RV involvement. Cardiac catheterization with coronary arteriography may be performed, particularly if primary percutaneous coronary intervention is feasible. (See
         <a class="medical medical_review" href="/z/d/html/75.html" rel="external">
          "Right ventricular myocardial infarction", section on 'Diagnosis'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Myocarditis presents variably with a spectrum of subacute or acute symptoms ranging from none to chest pain, fatigue, HF, and cardiogenic shock. Criteria have been developed to identify clinically suspected myocarditis, but a definitive diagnosis is generally made by biopsy (eg, endomyocardial and for some conditions, other affected tissue). Myocarditis may cause RHF through direct involvement of the RV and/or through involvement of the left ventricle (LV) and development of PH, which can cause RV pressure overload. (See
         <a class="medical medical_review" href="/z/d/html/4939.html" rel="external">
          "Clinical manifestations and diagnosis of myocarditis in adults"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/4922.html" rel="external">
          "Clinical manifestations and diagnosis of cardiac sarcoidosis", section on 'Diagnosis'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Precipitation of RHF in the setting of increased venous return [
         <a href="#rid5">
          5,6
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         High-output HF should be suspected in patients with HF but well-perfused extremities, particularly those with a condition commonly associated with a high-output state (eg, presence of an arteriovenous fistula for dialysis access [
         <a href="#rid7">
          7
         </a>
         ]). The diagnosis is confirmed by evaluation of hemodynamics by right heart catheterization. Patients with high-output HF frequently also have LV and/or RV systolic dysfunction, as seen in sepsis. (See
         <a class="medical medical_review" href="/z/d/html/3462.html" rel="external">
          "Causes and pathophysiology of high-output heart failure"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/113041.html" rel="external">
          "Clinical manifestations, diagnosis, and management of high-output heart failure"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/1657.html" rel="external">
          "Sepsis syndromes in adults: Epidemiology, definitions, clinical presentation, diagnosis, and prognosis"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/1613.html" rel="external">
          "Evaluation and management of suspected sepsis and septic shock in adults"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         LV assist device (LVAD) implantation may precipitate early or late (after initial hospital discharge) RHF. Following LVAD implantation, there is an increase in systemic venous return to the right heart; also, decreased LV pressure and chamber size after LVAD implantation cause interventricular septal bowing, which may worsen RV mechanics with decrease in RV stroke volume and increase in tricuspid regurgitation. Evaluation includes right heart catheterization and transthoracic echocardiography. Predictors of RHF after LVAD implantation include greater elevation in central venous pressure to pulmonary capillary wedge pressure (&gt;0.63), reduced pulmonary artery pulsatility index, and decreased RV stroke work index [
         <a href="#rid1">
          1
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/87834.html" rel="external">
          "Management of long-term mechanical circulatory support devices", section on 'Right heart failure'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Subacute or acute onset of dyspnea, often in the setting of a cause of pericardial effusion or hematoma (eg, viral syndrome, post-thoracic surgery).
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Cardiac tamponade may have a subacute or acute presentation, depending on speed of pericardial fluid accumulation and the clinical setting, with symptoms ranging from fatigue and dyspnea to shock. All causes of pericardial effusion may cause tamponade. The clinical diagnosis is generally based upon clinical evaluation, including echocardiography, and confirmed by the clinical and hemodynamic response to pericardial fluid drainage. Cardiac catheterization may be performed to confirm the presence of hemodynamic features consistent with tamponade. (See
         <a class="medical medical_review" href="/z/d/html/4921.html" rel="external">
          "Cardiac tamponade"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1989516303">
         <span class="h3">
          Chronic right heart failure
         </span>
         <span class="headingEndMark">
          —
         </span>
         The following cardiovascular disorders are causes of chronic RHF [
         <a href="#rid8">
          8-12
         </a>
         ]. These are generally distinguished largely by clinical presentation and initial testing, including echocardiography.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Chronic PH – PH in all etiologic groups  (
         <a class="graphic graphic_table graphicRef66348" href="/z/d/graphic/66348.html" rel="external">
          table 2
         </a>
         ) can cause RHF. The symptoms and signs of PH are nonspecific and include dyspnea and fatigue, exertional chest pain, exertional syncope, peripheral edema, anorexia and early satiety, and abdominal discomfort and swelling  (
         <a class="graphic graphic_table graphicRef138398" href="/z/d/graphic/138398.html" rel="external">
          table 3
         </a>
         ). Evaluation of suspected PH includes transthoracic echocardiography, which may provide an estimate of pulmonary artery systolic pressure and guide further evaluation, as discussed separately. Among patients with RHF of uncertain cause, echocardiographic findings suggestive of PH and RV dysfunction (eg, elevated left atrial pressures or pulmonary vascular disease) are the most common indications for cardiac catheterization  (
         <a class="graphic graphic_table graphicRef138398" href="/z/d/graphic/138398.html" rel="external">
          table 3
         </a>
         ). Identification of the cause of PH is important since this guides management. (See
         <a class="medical medical_review" href="/z/d/html/8249.html" rel="external">
          "Clinical features and diagnosis of pulmonary hypertension of unclear etiology in adults"
         </a>
         and
         <a class="local">
          'Specific therapy'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Some of the more common causes are highlighted here:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         PH due to left heart disease (group 2) – PH in patients with left HF is due to both passive backward transmission of left atrial hypertension, as well as pulmonary vasoconstriction and vascular remodeling that opposes blood flow through the lungs [
         <a href="#rid13">
          13
         </a>
         ]. Diagnostic evaluation includes transthoracic echocardiography, which helps determine whether right heart catheterization is indicated. (See
         <a class="medical medical_review" href="/z/d/html/112486.html" rel="external">
          "Pulmonary hypertension due to left heart disease (group 2 pulmonary hypertension) in adults", section on 'Diagnosis and evaluation'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         Common causes of PH due to left heart disease include the following conditions (see
         <a class="medical medical_review" href="/z/d/html/112486.html" rel="external">
          "Pulmonary hypertension due to left heart disease (group 2 pulmonary hypertension) in adults"
         </a>
         ):
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         HF with reduced ejection fraction (HFrEF) and HF with mid-range ejection fraction (HFmrEF) – In patients with HF, a diagnosis of HFrEF is generally confirmed by identification of an LV ejection fraction (LVEF) ≤40 percent (most commonly by echocardiography); a diagnosis of HFmrEF is generally confirmed by identification of an LVEF of 41 to 49 percent. HFrEF (and HFmrEF) may be caused by nonischemic (eg, dilated cardiomyopathy, myocarditis) or ischemic heart disease. (See
         <a class="medical medical_review" href="/z/d/html/3510.html" rel="external">
          "Heart failure: Clinical manifestations and diagnosis in adults"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/3485.html" rel="external">
          "Determining the etiology and severity of heart failure or cardiomyopathy"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         HF with preserved ejection fraction (HFpEF) – In patients with HF with preserved ejection fraction (HFpEF), the LVEF is (by definition) ≥50 percent, which may make diagnosis more challenging [
         <a href="#rid14">
          14
         </a>
         ]. Physical examination findings, echocardiographic values, and natriuretic peptide levels are generally more abnormal in patients with HFpEF and RHF as compared with patients with HFpEF and no RHF [
         <a href="#rid2">
          2,15
         </a>
         ]. The approach to diagnosis of HFpEF is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/3504.html" rel="external">
          "Heart failure with preserved ejection fraction: Clinical manifestations and diagnosis", section on 'Evaluation'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         Some patients present with RHF with no clear evidence of provocative factors, and many of these patients have RHF due to previously undiagnosed HFpEF. In a longitudinal study of patients who presented initially with HFpEF and isolated left heart involvement, the incidence of new-onset RV dysfunction was 23 percent over just four years [
         <a href="#rid16">
          16
         </a>
         ]. Over sustained periods of time, ventricular dilation and deterioration in systolic function are much greater in the RV than the LV in HFpEF, and RHF may be an indicator of the duration of left-sided HF [
         <a href="#rid16">
          16
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         HF due to left-sided valve disease (mitral or aortic; stenosis or regurgitation). (See
         <a class="medical medical_review" href="/z/d/html/8116.html" rel="external">
          "Clinical manifestations and diagnosis of chronic mitral regurgitation"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/8173.html" rel="external">
          "Rheumatic mitral stenosis: Clinical manifestations and diagnosis"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/8159.html" rel="external">
          "Clinical manifestations and diagnosis of chronic aortic regurgitation in adults"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/8164.html" rel="external">
          "Clinical manifestations and diagnosis of aortic stenosis in adults"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Pulmonary arterial hypertension (group 1). Evaluation is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/8249.html" rel="external">
          "Clinical features and diagnosis of pulmonary hypertension of unclear etiology in adults"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/8247.html" rel="external">
          "The epidemiology and pathogenesis of pulmonary arterial hypertension (Group 1)"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         PH due to lung disease and/or hypoxia (group 3), including the following causes (see
         <a class="medical medical_review" href="/z/d/html/112486.html" rel="external">
          "Pulmonary hypertension due to left heart disease (group 2 pulmonary hypertension) in adults"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/8258.html" rel="external">
          "Pulmonary hypertension due to lung disease and/or hypoxemia (group 3 pulmonary hypertension): Treatment and prognosis"
         </a>
         ):
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Obstructive sleep apnea. (See
         <a class="medical medical_review" href="/z/d/html/7706.html" rel="external">
          "Clinical presentation and diagnosis of obstructive sleep apnea in adults"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Obstructive and/or restrictive lung disease. (See
         <a class="medical medical_review" href="/z/d/html/1455.html" rel="external">
          "Chronic obstructive pulmonary disease: Diagnosis and staging"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/4310.html" rel="external">
          "Approach to the adult with interstitial lung disease: Clinical evaluation"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/4320.html" rel="external">
          "Chest wall diseases and restrictive physiology"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Congenital heart disease – Congenital heart lesions that cause RHF are generally identified by clinical evaluation and echocardiography and include lesions causing RV volume overload, conditions causing RV pressure overload (due to PH and/or RV outflow obstruction), congenital causes of right-sided valve disease, and conditions associated with primary RV dysfunction or absence (including patients with anatomic or functional single ventricle treated with a Fontan procedure) [
         <a href="#rid17">
          17
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Congenital lesions causing RV volume overload include atrial septal defects, tricuspid regurgitation, or pulmonic regurgitation. (See
         <a class="medical medical_review" href="/z/d/html/1418.html" rel="external">
          "Clinical manifestations and diagnosis of atrial septal defects in adults"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/8146.html" rel="external">
          "Ebstein anomaly: Clinical manifestations and diagnosis"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/104752.html" rel="external">
          "Pulmonic regurgitation"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         PH in patients with congenital heart disease is predominantly group 1 and less commonly group 2; groups 3, 4, and 5 also occur. Group 5 includes some complex congenital heart disease. Various types of intracardiac shunts (eg, ventricular septal defects, atrial septal defects) and aortic shunts (eg, patent ductus arteriosus) increase pulmonary blood flow, leading to progressive pulmonary vascular disease and group 1 PH, with some cases progressing to Eisenmenger syndrome. (See
         <a class="medical medical_review" href="/z/d/html/105507.html" rel="external">
          "Pulmonary hypertension with congenital heart disease: Clinical manifestations and diagnosis"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Right ventricular outflow obstruction is a component of tetralogy of Fallot, and some patients have residual RV outflow obstruction after surgical repair. (See
         <a class="medical medical_review" href="/z/d/html/5769.html" rel="external">
          "Tetralogy of Fallot (TOF): Pathophysiology, clinical features, and diagnosis", section on 'Right ventricular outflow tract obstruction'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/141526.html" rel="external">
          "Tetralogy of Fallot (TOF): Long-term complications and follow-up after repair", section on 'Residual RVOT obstruction'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         In Fontan patients, there is no ventricular pump to push blood into the pulmonary arterial circulation, so systemic venous pressures are chronically elevated. Even small elevations in pulmonary vascular resistance in these patients substantially compromise blood flow and lead to increased risk of RHF due to the absence of a subpulmonary ventricle [
         <a href="#rid18">
          18
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/95232.html" rel="external">
          "Management of complications in patients with Fontan circulation", section on 'Heart failure'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Right-sided valve disease – Right-sided valve (tricuspid or pulmonic) diseases (regurgitation or stenosis) are generally identified and characterized by physical examination and echocardiography. These valve lesions may be congenital (eg, Ebstein anomaly with tricuspid regurgitation) or acquired (eg, right-sided valve dysfunction caused by endocarditis). Patients with atrial fibrillation frequently develop tricuspid regurgitation related to dilation of the tricuspid annulus and tricuspid regurgitation, causing RHF related to volume overload even in the absence of an elevation in pulmonary artery pressure [
         <a href="#rid8">
          8,9,16,19
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Cardiomyopathies – Cardiomyopathies involving the RV and/or LV may cause RHF, including dilated and restrictive cardiomyopathies, as well as arrhythmogenic right ventricular cardiomyopathy [
         <a href="#rid20">
          20
         </a>
         ]. Echocardiography and other cardiac imaging (particularly cardiovascular magnetic resonance imaging) are used to identify and characterize these disorders. (See
         <a class="medical medical_review" href="/z/d/html/4943.html" rel="external">
          "Definition and classification of the cardiomyopathies"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/4918.html" rel="external">
          "Restrictive cardiomyopathies"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/4931.html" rel="external">
          "Arrhythmogenic right ventricular cardiomyopathy: Anatomy, histology, and clinical manifestations"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/4929.html" rel="external">
          "Arrhythmogenic right ventricular cardiomyopathy: Pathogenesis and genetics"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/110459.html" rel="external">
          "Arrhythmogenic right ventricular cardiomyopathy: Diagnostic evaluation and diagnosis"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Constrictive pericarditis should be suspected in patients with RHF with prior history of a potential cause of pericardial constriction (eg, prior thoracic radiation exposure or prior cardiac surgery) and is generally diagnosed by echocardiography with selective use of additional cross-sectional imaging (computed tomography or magnetic resonance imaging). Combined left and right heart catheterization is the clinical gold standard for distinguishing pericardial disease from cardiac causes of RHF (such as restrictive cardiomyopathy). Testing to distinguish these conditions is discussed further separately. (See
         <a class="medical medical_review" href="/z/d/html/4938.html" rel="external">
          "Constrictive pericarditis: Diagnostic evaluation", section on 'Initial tests'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/4946.html" rel="external">
          "Differentiating constrictive pericarditis and restrictive cardiomyopathy"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H879977613">
         <span class="h1">
          MANAGEMENT
         </span>
        </p>
        <p class="headingAnchor" id="H460386779">
         <span class="h2">
          General management
         </span>
         <span class="headingEndMark">
          —
         </span>
         General management includes maintaining oxygen delivery to the tissues, monitoring optimizing volume status, hemodynamic support, arrhythmia management, advanced therapies for refractory HF, palliative care, and activity restriction. (See
         <a class="medical medical_review" href="/z/d/html/3454.html" rel="external">
          "Treatment of acute decompensated heart failure: General considerations"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/3450.html" rel="external">
          "Treatment of acute decompensated heart failure: Specific therapies"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/121085.html" rel="external">
          "Overview of the management of heart failure with reduced ejection fraction in adults"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/3461.html" rel="external">
          "Treatment and prognosis of heart failure with preserved ejection fraction"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3492509773">
         <span class="h3">
          Supplemental oxygen and ventilatory support
         </span>
         <span class="headingEndMark">
          —
         </span>
         Supplemental oxygen is used as needed to treat hypoxemia (
         <sub>
          S
         </sub>
         pO
         <sub>
          2
         </sub>
         &lt;90 percent) with assisted ventilation if needed. In addition to supporting O
         <sub>
          2
         </sub>
         delivery to the body, this intervention may also help to reduce hypoxic vasoconstriction in the lungs that contributes to pulmonary hypertension (PH). (See
         <a class="medical medical_review" href="/z/d/html/3450.html" rel="external">
          "Treatment of acute decompensated heart failure: Specific therapies", section on 'Supplemental oxygen and assisted ventilation'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2126494559">
         <span class="h3">
          Monitoring and sodium and fluid restriction
         </span>
         <span class="headingEndMark">
          —
         </span>
         Measures for acute HF care as well as outpatient HF self-management include daily monitoring of symptoms, signs, and weight. General guidelines for sodium restriction (eg, &lt;3 g/day) and fluid restriction (eg, 1.5 to 2 L/day) apply, although evidence for specific thresholds are limited. (See
         <a class="medical medical_review" href="/z/d/html/3454.html" rel="external">
          "Treatment of acute decompensated heart failure: General considerations", section on 'Monitoring'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/3450.html" rel="external">
          "Treatment of acute decompensated heart failure: Specific therapies", section on 'Sodium and fluid restriction'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/13607.html" rel="external">
          "Heart failure self-management"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2402005460">
         <span class="h3">
          Optimization of volume status
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Volume overload is generally treated with diuretic therapy. Ultrafiltration is an option for patients with refractory volume overload. (See
         <a class="medical medical_review" href="/z/d/html/3512.html" rel="external">
          "Use of diuretics in patients with heart failure"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Volume overload in patients with acute or chronic RHF due to left HF or RV volume overload due to tricuspid or pulmonic regurgitation are treated with diuretic therapy. In patients with RHF due to left HF, diuretics are a mainstay of therapy to reduce right and left heart filling pressures. Treating left HF will reduce RV afterload by decreasing pulmonary artery pressures [
         <a href="#rid21">
          21
         </a>
         ] and also by increasing pulmonary artery compliance [
         <a href="#rid22">
          22
         </a>
         ]. Patients with RHF frequently have concurrent acute and chronic kidney disease (including cardiorenal syndrome) and often require very high doses of diuretics, typically administered intravenously because gut edema limits oral absorption [
         <a href="#rid23">
          23-26
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/3512.html" rel="external">
          "Use of diuretics in patients with heart failure"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/112486.html" rel="external">
          "Pulmonary hypertension due to left heart disease (group 2 pulmonary hypertension) in adults", section on 'Optimized management of left heart disease'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/15619.html" rel="external">
          "Cardiorenal syndrome: Prognosis and treatment"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Diuretic therapy is used to treat volume overload in selected patients with RV pressure overload (eg, patients with group 1 pulmonary arterial hypertension or tricuspid stenosis), but volume depletion should be avoided given the risk of hemodynamic decompensation. (See
         <a class="medical medical_review" href="/z/d/html/121912.html" rel="external">
          "Treatment and prognosis of pulmonary arterial hypertension in adults (group 1)", section on 'Diuretics (treatment of chronic right heart failure)'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/8136.html" rel="external">
          "Tricuspid stenosis", section on 'Medical management'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Avoidance of volume depletion is particularly important in the following clinical settings: pulmonary embolism, cardiac tamponade, RVMI, and PH associated with congenital heart disease. (See
         <a class="medical medical_review" href="/z/d/html/8265.html" rel="external">
          "Treatment, prognosis, and follow-up of acute pulmonary embolism in adults", section on 'Hemodynamic support'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/75.html" rel="external">
          "Right ventricular myocardial infarction", section on 'Optimization of right ventricular preload'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/119400.html" rel="external">
          "Pulmonary hypertension in adults with congenital heart disease: General management and prognosis", section on 'Volume depletion or systemic vasodilation'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/4921.html" rel="external">
          "Cardiac tamponade", section on 'Supportive care'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Volume repletion – When volume repletion is indicated, this is generally performed by carefully monitored intravenous fluid challenges (eg, aliquots of 200 to 300 mL of normal
         <a class="drug drug_general" data-topicid="9929" href="/z/d/drug information/9929.html" rel="external">
          saline
         </a>
         over five minutes).
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Patients with acute pulmonary embolism with hypotension or other signs of low cardiac output (hypoperfusion) are generally treated with volume repletion (generally limited to a total of no more than 500 to 1000 mL of normal
         <a class="drug drug_general" data-topicid="9929" href="/z/d/drug information/9929.html" rel="external">
          saline
         </a>
         ), which is followed by vasopressor therapy if hypoperfusion persists. (See
         <a class="medical medical_review" href="/z/d/html/8265.html" rel="external">
          "Treatment, prognosis, and follow-up of acute pulmonary embolism in adults", section on 'Hemodynamic support'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         For patients with cardiac tamponade with hypotension or other signs of low cardiac output, volume repletion is a temporizing measure until pericardial fluid drainage is performed. (See
         <a class="medical medical_review" href="/z/d/html/4921.html" rel="external">
          "Cardiac tamponade", section on 'Supportive care'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         For patients with RVMI with evidence of low cardiac output, no pulmonary congestion, and low or normal jugular venous pressure, volume repletion is performed to enhance RV preload. (See
         <a class="medical medical_review" href="/z/d/html/75.html" rel="external">
          "Right ventricular myocardial infarction", section on 'Optimization of right ventricular preload'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2786446169">
         <span class="h3">
          Arrhythmia management
         </span>
         <span class="headingEndMark">
          —
         </span>
         Complications in patients with RHF may include conduction system disease and arrhythmias. Management of these conditions and the risk of sudden death are based upon general treatment principles along with specific approaches for certain causes of RHF, as discussed in individual topic reviews. (See
         <a class="medical medical_review" href="/z/d/html/121085.html" rel="external">
          "Overview of the management of heart failure with reduced ejection fraction in adults", section on 'Arrhythmias and conduction system disease'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/4932.html" rel="external">
          "Arrhythmogenic right ventricular cardiomyopathy: Treatment and prognosis"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/113686.html" rel="external">
          "Management and prognosis of cardiac sarcoidosis"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/113686.html" rel="external">
          "Management and prognosis of cardiac sarcoidosis", section on 'Management of arrhythmias and conduction system disease'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/3461.html" rel="external">
          "Treatment and prognosis of heart failure with preserved ejection fraction", section on 'Atrial fibrillation'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2079476396">
         <span class="h3">
          Activity restriction
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients with symptomatic HF, active myocarditis, pericardial effusion, or constrictive pericarditis are generally restricted from competitive sports [
         <a href="#rid27">
          27
         </a>
         ]. Specific recommendations apply to certain types of cardiomyopathy, including arrhythmogenic right ventricular cardiomyopathy and myocarditis. (See
         <a class="medical medical_review" href="/z/d/html/986.html" rel="external">
          "Athletes: Overview of sudden cardiac death risk and sport participation"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1737360787">
         <span class="h2">
          Specific therapy
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients with certain causes of RHF are treated with the appropriate specific therapies, in addition to the above general measures.
        </p>
        <p class="headingAnchor" id="H3033370994">
         <span class="h3">
          For acute right heart failure
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Management of acute pulmonary embolism with RHF includes treatment to address thromboembolism (anticoagulation for stable patients; reperfusion by thrombolysis or thrombectomy for unstable patients) in addition to the supportive care described above. (See
         <a class="medical medical_review" href="/z/d/html/8265.html" rel="external">
          "Treatment, prognosis, and follow-up of acute pulmonary embolism in adults"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         RVMI is treated with reperfusion (primary percutaneous coronary intervention or fibrinolysis) and other therapy for MI (in addition to measures to optimize volume status and provide hemodynamic support, as described above). (See
         <a class="medical medical_review" href="/z/d/html/75.html" rel="external">
          "Right ventricular myocardial infarction", section on 'Treatment'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Certain forms of myocarditis that may cause acute RHF (eg, giant cell myocarditis and necrotizing eosinophilic myocarditis) are treated with immunosuppressive therapy, as discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/4935.html" rel="external">
          "Treatment and prognosis of myocarditis in adults"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/4935.html" rel="external">
          "Treatment and prognosis of myocarditis in adults", section on 'Giant cell myocarditis'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/4935.html" rel="external">
          "Treatment and prognosis of myocarditis in adults", section on 'Eosinophilic myocarditis'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Cardiac tamponade is treated by removal of pericardial fluid, either percutaneously (pericardiocentesis) or surgically. (See
         <a class="medical medical_review" href="/z/d/html/143123.html" rel="external">
          "Pericardial effusion: Approach to management"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In patients with RHF following LV assist device (LVAD) placement, LVAD settings are adjusted to minimize interventricular septal bowing on echocardiography. Additional measures may be required, including inotropic support, RV mechanical support, or extracorporeal membrane oxygenation. (See
         <a class="medical medical_review" href="/z/d/html/87834.html" rel="external">
          "Management of long-term mechanical circulatory support devices", section on 'Right heart failure'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Superior or inferior vena cava obstruction may present with acute or chronic symptoms. Management of these conditions is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/2832.html" rel="external">
          "Malignancy-related superior vena cava syndrome", section on 'Treatment'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/15223.html" rel="external">
          "Overview of iliocaval venous obstruction", section on 'Management'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3850897649">
         <span class="h3">
          For chronic right heart failure
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Patients with RHF and HF with reduced ejection fraction (HFrEF) or HF with mid-range ejection fraction should be treated with standard guideline-directed pharmacologic and device therapy as tolerated [
         <a href="#rid28">
          28
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/121085.html" rel="external">
          "Overview of the management of heart failure with reduced ejection fraction in adults"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/121086.html" rel="external">
          "Primary pharmacologic therapy for heart failure with reduced ejection fraction"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/121087.html" rel="external">
          "Secondary pharmacologic therapy for heart failure with reduced ejection fraction"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Pulmonary vasodilator therapies are used to treat patients with RHF due to pulmonary arterial hypertension group 1  (
         <a class="graphic graphic_table graphicRef66348" href="/z/d/graphic/66348.html" rel="external">
          table 2
         </a>
         ); selected patients with PH groups 2, 3, or 4 may be candidates for some of these agents, as discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/8250.html" rel="external">
          "Treatment of pulmonary arterial hypertension (group 1) in adults: Pulmonary hypertension-specific therapy"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/112486.html" rel="external">
          "Pulmonary hypertension due to left heart disease (group 2 pulmonary hypertension) in adults", section on 'Targeted therapy for pulmonary hypertension'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/8258.html" rel="external">
          "Pulmonary hypertension due to lung disease and/or hypoxemia (group 3 pulmonary hypertension): Treatment and prognosis", section on 'Our approach'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/16628.html" rel="external">
          "Chronic thromboembolic pulmonary hypertension: Pulmonary hypertension-specific therapy"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/95232.html" rel="external">
          "Management of complications in patients with Fontan circulation"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/95232.html" rel="external">
          "Management of complications in patients with Fontan circulation", section on 'Pulmonary vasodilator therapy'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Certain forms of myocarditis that may cause chronic RHF (eg, cardiac sarcoidosis) are treated with immunosuppressive therapy. (See
         <a class="medical medical_review" href="/z/d/html/113686.html" rel="external">
          "Management and prognosis of cardiac sarcoidosis", section on 'Immunosuppressive therapies'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/4935.html" rel="external">
          "Treatment and prognosis of myocarditis in adults", section on 'Management of specific disorders'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The management of arrhythmogenic RV cardiomyopathy includes measures to prevent sudden cardiac death, treat symptomatic arrhythmias, and reduce the risk of progression. (See
         <a class="medical medical_review" href="/z/d/html/4932.html" rel="external">
          "Arrhythmogenic right ventricular cardiomyopathy: Treatment and prognosis"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Patients with chronic thromboembolic PH are treated with anticoagulant therapy and should be referred for evaluation for pulmonary thromboendarterectomy. (See
         <a class="medical medical_review" href="/z/d/html/16637.html" rel="external">
          "Chronic thromboembolic pulmonary hypertension: Initial management and evaluation for pulmonary artery thromboendarterectomy"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Specific interventions (eg, surgery or percutaneous techniques) are indicated for patients with congenital heart disease; an example is atrial septal defect closure in patients with a hemodynamically significant left-to-right shunt without significant PH. Valve surgery is indicated for patients with symptomatic severe right- or left-heart valve dysfunction (regurgitation or stenosis), as discussed in individual topic reviews. (See
         <a class="medical medical_review" href="/z/d/html/8145.html" rel="external">
          "Management and prognosis of tricuspid regurgitation", section on 'Tricuspid valve surgery'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/8118.html" rel="external">
          "Pulmonic valve stenosis in adults: Management", section on 'Indications for intervention'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/8136.html" rel="external">
          "Tricuspid stenosis", section on 'Indications for intervention'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/104752.html" rel="external">
          "Pulmonic regurgitation", section on 'Intervention'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Early stage (subacute) hemodynamically stable constrictive pericarditis may respond to a trial of antiinflammatory therapy (a nonsteroidal antiinflammatory agent plus
         <a class="drug drug_general" data-topicid="9293" href="/z/d/drug information/9293.html" rel="external">
          colchicine
         </a>
         ), but refractory patients and those with late-stage constrictive pericarditis should be referred for surgical pericardiectomy. (See
         <a class="medical medical_review" href="/z/d/html/140886.html" rel="external">
          "Constrictive pericarditis: Management and prognosis", section on 'Management of constrictive pericarditis'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2187245945">
         <span class="h2">
          Management of refractory heart failure
         </span>
         <span class="headingEndMark">
          —
         </span>
         Management of refractory RHF depends on the clinical presentation and cause.
        </p>
        <p class="headingAnchor" id="H3449871866">
         <span class="h3">
          Approach to refractory volume overload
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients with refractory volume overload despite initial diuretic therapy are treated with uptitration of diuretic dose and diuretic combinations as discussed separately. If these measures are unsuccessful, hemodialysis or hemofiltration can be used for fluid removal. (See
         <a class="medical medical_review" href="/z/d/html/2324.html" rel="external">
          "Causes and treatment of refractory edema in adults"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/2324.html" rel="external">
          "Causes and treatment of refractory edema in adults", section on 'Management of refractory edema'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H394626086">
         <span class="h3">
          Approach to low cardiac output
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients with evidence of low cardiac output with hypoperfusion caused by RV and/or LV systolic dysfunction are treated with intravenous inotropes as a temporizing measure, while treatment for specific causes is provided (see
         <a class="local">
          'Specific therapy'
         </a>
         above). As an example, patients with acute MI complicated by acute RV systolic dysfunction may be treated with an inotrope, vasopressor therapy, and/or fluid resuscitation until revascularization and RV recovery occur. (See
         <a class="medical medical_review" href="/z/d/html/75.html" rel="external">
          "Right ventricular myocardial infarction", section on 'Inotropic drugs'
         </a>
         .)
        </p>
        <p>
         For patients with acute RHF with HFrEF, intravenous systemic vasodilators may help improve forward flow [
         <a href="#rid29">
          29,30
         </a>
         ]. The use of pulmonary vasodilator therapy for selected patients with PH is discussed elsewhere in this topic. (See
         <a class="medical medical_review" href="/z/d/html/3450.html" rel="external">
          "Treatment of acute decompensated heart failure: Specific therapies", section on 'Vasodilator therapy'
         </a>
         and
         <a class="local">
          'For chronic right heart failure'
         </a>
         above.)
        </p>
        <p>
         For patients with isolated RHF, a role for
         <a class="drug drug_general" data-topicid="9360" href="/z/d/drug information/9360.html" rel="external">
          digoxin
         </a>
         therapy has not been established, as evidence in this setting is scant [
         <a href="#rid1">
          1,31
         </a>
         ]. A systematic review included four small randomized controlled trials with a total of 76 patients with RHF due to cor pulmonale [
         <a href="#rid32">
          32
         </a>
         ]. The review found no association between digoxin therapy and improvement in New York Heart Association (NYHA) functional class, exercise capacity, or RV ejection fraction. In contrast, digoxin is an established component of therapy in selected patients with HFrEF (including those with RHF) and persistent symptoms while on optimized guideline-directed medical therapy. (See
         <a class="local">
          'Specific therapy'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/121087.html" rel="external">
          "Secondary pharmacologic therapy for heart failure with reduced ejection fraction"
         </a>
         .)
        </p>
        <p>
         Mechanical circulatory support is indicated for patients with severe RHF due to LV or RV systolic dysfunction with refractory HF [
         <a href="#rid4">
          4,33
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/3459.html" rel="external">
          "Treatment of advanced heart failure with a durable mechanical circulatory support device", section on 'Device types for common patient groups'
         </a>
         .)
        </p>
        <p>
         Heart or combined heart-lung transplantation is required in some cases of refractory HF due to LV and/or RV dysfunction. (See
         <a class="medical medical_review" href="/z/d/html/3528.html" rel="external">
          "Heart transplantation in adults: Indications and contraindications", section on 'Indications for transplantation'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1359928169">
         <span class="h3">
          Role of palliative care
         </span>
         <span class="headingEndMark">
          —
         </span>
         Supportive primary palliative care is an important component of care for patients with RHF to address symptom control, goals of care, shared decision-making, and execution of advanced care directives. Secondary palliative care is indicated for patients with persistent NYHA functional class IV, with significant comorbidities or progressive frailty, facing decision-making on major interventions (such as mechanical circulatory support), or with preferences shifting the emphasis of care to quality of life. (See
         <a class="medical medical_review" href="/z/d/html/3511.html" rel="external">
          "Palliative care for patients with advanced heart failure: Indications and systems of care"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/110747.html" rel="external">
          "Palliative care for patients with advanced heart failure: Decision support and management of symptoms"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1245916818">
         <span class="h1">
          PROGNOSIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Outcomes are highly variable for RHF and depend on the underlying etiology. In general, the presence of RHF or RV dysfunction is among the strongest predictors for adverse outcomes for patients with HF with reduced ejection fraction, HF with preserved ejection fraction, or non-HF-related pulmonary hypertension [
         <a href="#rid8">
          8,9,11,34
         </a>
         ]. Further details on prognosis can be found in the individual topics for specific causes of RHF.
        </p>
        <p class="headingAnchor" id="H778756922">
         <span class="h1">
          SOCIETY GUIDELINE LINKS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/115372.html" rel="external">
          "Society guideline links: Heart failure in adults"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1943806360">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Evaluating the cause of right heart failure
         </strong>
         – The process of evaluating the cause of right heart failure (RHF) overlaps the process of diagnosing RHF, starting with assessment of clinical manifestations and diagnostic testing  (
         <a class="graphic graphic_table graphicRef138398" href="/z/d/graphic/138398.html" rel="external">
          table 3
         </a>
         ). (See
         <a class="local">
          'Evaluating the cause of right heart failure'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/126513.html" rel="external">
          "Right heart failure: Clinical manifestations and diagnosis", section on 'Clinical manifestations'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Acute right heart failure
         </strong>
         – Causes of acute RHF include causes of acute dyspnea and pulmonary hypertension (PH; such as pulmonary embolism and adult respiratory distress syndrome), causes of primary right ventricular (RV) dysfunction (such as RV myocardial infarction [RVMI] and myocarditis), disorders associated with increased venous return (such as sepsis and RHF after left ventricular assist device implantation), and cardiac tamponade. (See
         <a class="local">
          'Acute right heart failure'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Chronic right heart failure
         </strong>
         – Causes of chronic RHF include causes of chronic PH (including PH due to left heart disease), various types of congenital heart disease that cause RV volume or pressure overload or RV dysfunction, right-sided valve disease, cardiomyopathies, and constrictive pericarditis. (See
         <a class="local">
          'Chronic right heart failure'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Management
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          General management
         </strong>
         – General management of RHF includes maintaining oxygen delivery to the tissues, monitoring optimizing volume status, hemodynamic support, arrhythmia management, and activity restriction. (See
         <a class="local">
          'General management'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Specific therapies
         </strong>
         – Certain causes of RHF are treated with the appropriate specific therapies. Examples include myocardial reperfusion for patients with RVMI and pericardiectomy for patients with late-stage constrictive pericarditis. (See
         <a class="local">
          'Specific therapy'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Management of refractory right heart failure
         </strong>
         – Management of refractory RHF includes management of refractory volume overload (with optimized diuretic therapy and if unsuccessful, with hemofiltration), management of low cardiac output (options include intravenous inotropes, mechanical support, and in some cases, heart or heart-lung transplantation), and palliative care. (See
         <a class="local">
          'Management of refractory heart failure'
         </a>
         above.)
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Konstam MA, Kiernan MS, Bernstein D, et al. Evaluation and Management of Right-Sided Heart Failure: A Scientific Statement From the American Heart Association. Circulation 2018; 137:e578.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gorter TM, van Veldhuisen DJ, Bauersachs J, et al. Right heart dysfunction and failure in heart failure with preserved ejection fraction: mechanisms and management. Position statement on behalf of the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail 2018; 20:16.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mehra MR, Park MH, Landzberg MJ, et al. Right heart failure: toward a common language. J Heart Lung Transplant 2014; 33:123.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Harjola VP, Mebazaa A, Čelutkienė J, et al. Contemporary management of acute right ventricular failure: a statement from the Heart Failure Association and the Working Group on Pulmonary Circulation and Right Ventricular Function of the European Society of Cardiology. Eur J Heart Fail 2016; 18:226.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Haddad F, Couture P, Tousignant C, Denault AY. The right ventricle in cardiac surgery, a perioperative perspective: I. Anatomy, physiology, and assessment. Anesth Analg 2009; 108:407.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Haddad F, Couture P, Tousignant C, Denault AY. The right ventricle in cardiac surgery, a perioperative perspective: II. Pathophysiology, clinical importance, and management. Anesth Analg 2009; 108:422.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Reddy YNV, Obokata M, Dean PG, et al. Long-term cardiovascular changes following creation of arteriovenous fistula in patients with end stage renal disease. Eur Heart J 2017; 38:1913.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Melenovsky V, Hwang SJ, Lin G, et al. Right heart dysfunction in heart failure with preserved ejection fraction. Eur Heart J 2014; 35:3452.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mohammed SF, Hussain I, AbouEzzeddine OF, et al. Right ventricular function in heart failure with preserved ejection fraction: a community-based study. Circulation 2014; 130:2310.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Di Salvo TG, Mathier M, Semigran MJ, Dec GW. Preserved right ventricular ejection fraction predicts exercise capacity and survival in advanced heart failure. J Am Coll Cardiol 1995; 25:1143.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fine NM, Chen L, Bastiansen PM, et al. Outcome prediction by quantitative right ventricular function assessment in 575 subjects evaluated for pulmonary hypertension. Circ Cardiovasc Imaging 2013; 6:711.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gulati A, Ismail TF, Jabbour A, et al. The prevalence and prognostic significance of right ventricular systolic dysfunction in nonischemic dilated cardiomyopathy. Circulation 2013; 128:1623.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Guazzi M, Borlaug BA. Pulmonary hypertension due to left heart disease. Circulation 2012; 126:975.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pfeffer MA, Shah AM, Borlaug BA. Heart Failure With Preserved Ejection Fraction In Perspective. Circ Res 2019; 124:1598.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Verbrugge FH, Omote K, Reddy YNV, et al. Heart failure with preserved ejection fraction in patients with normal natriuretic peptide levels is associated with increased morbidity and mortality. Eur Heart J 2022; 43:1941.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Obokata M, Reddy YNV, Melenovsky V, et al. Deterioration in right ventricular structure and function over time in patients with heart failure and preserved ejection fraction. Eur Heart J 2019; 40:689.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Stout KK, Daniels CJ, Aboulhosn JA, et al. 2018 AHA/ACC Guideline for the Management of Adults With Congenital Heart Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation 2019; 139:e698.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Egbe AC, Connolly HM, Miranda WR, et al. Hemodynamics of Fontan failure: The role of pulmonary vascular disease. Circ Heart Fail 2017; 10.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zhao SX, Soltanzad N, Swaminathan A, et al. Frequency and Associated Clinical Features of Functional Tricuspid Regurgitation in Patients With Chronic Atrial Fibrillation. Am J Cardiol 2017; 119:1371.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Corrado D, van Tintelen PJ, McKenna WJ, et al. Arrhythmogenic right ventricular cardiomyopathy: evaluation of the current diagnostic criteria and differential diagnosis. Eur Heart J 2020; 41:1414.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vonk Noordegraaf A, Westerhof BE, Westerhof N. The Relationship Between the Right Ventricle and its Load in Pulmonary Hypertension. J Am Coll Cardiol 2017; 69:236.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tedford RJ, Hassoun PM, Mathai SC, et al. Pulmonary capillary wedge pressure augments right ventricular pulsatile loading. Circulation 2012; 125:289.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mullens W, Abrahams Z, Francis GS, et al. Importance of venous congestion for worsening of renal function in advanced decompensated heart failure. J Am Coll Cardiol 2009; 53:589.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Damman K, van Deursen VM, Navis G, et al. Increased central venous pressure is associated with impaired renal function and mortality in a broad spectrum of patients with cardiovascular disease. J Am Coll Cardiol 2009; 53:582.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Testani JM, Khera AV, St John Sutton MG, et al. Effect of right ventricular function and venous congestion on cardiorenal interactions during the treatment of decompensated heart failure. Am J Cardiol 2010; 105:511.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Testani JM, Chen J, McCauley BD, et al. Potential effects of aggressive decongestion during the treatment of decompensated heart failure on renal function and survival. Circulation 2010; 122:265.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Maron BJ, Udelson JE, Bonow RO, et al. Eligibility and Disqualification Recommendations for Competitive Athletes With Cardiovascular Abnormalities: Task Force 3: Hypertrophic Cardiomyopathy, Arrhythmogenic Right Ventricular Cardiomyopathy and Other Cardiomyopathies, and Myocarditis: A Scientific Statement From the American Heart Association and American College of Cardiology. Circulation 2015; 132:e273.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           WRITING COMMITTEE MEMBERS, Yancy CW, Jessup M, et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation 2013; 128:e240.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schwartzenberg S, Redfield MM, From AM, et al. Effects of vasodilation in heart failure with preserved or reduced ejection fraction implications of distinct pathophysiologies on response to therapy. J Am Coll Cardiol 2012; 59:442.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mullens W, Abrahams Z, Francis GS, et al. Sodium nitroprusside for advanced low-output heart failure. J Am Coll Cardiol 2008; 52:200.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rich S, Seidlitz M, Dodin E, et al. The short-term effects of digoxin in patients with right ventricular dysfunction from pulmonary hypertension. Chest 1998; 114:787.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Alajaji W, Baydoun A, Al-Kindi SG, et al. Digoxin therapy for cor pulmonale: A systematic review. Int J Cardiol 2016; 223:320.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kapur NK, Esposito ML, Bader Y, et al. Mechanical Circulatory Support Devices for Acute Right Ventricular Failure. Circulation 2017; 136:314.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ghio S, Gavazzi A, Campana C, et al. Independent and additive prognostic value of right ventricular systolic function and pulmonary artery pressure in patients with chronic heart failure. J Am Coll Cardiol 2001; 37:183.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 127128 Version 10.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29650544" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Evaluation and Management of Right-Sided Heart Failure: A Scientific Statement From the American Heart Association.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29044932" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Right heart dysfunction and failure in heart failure with preserved ejection fraction: mechanisms and management. Position statement on behalf of the Heart Failure Association of the European Society of Cardiology.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24268184" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Right heart failure: toward a common language.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26995592" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Contemporary management of acute right ventricular failure: a statement from the Heart Failure Association and the Working Group on Pulmonary Circulation and Right Ventricular Function of the European Society of Cardiology.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19151264" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : The right ventricle in cardiac surgery, a perioperative perspective: I. Anatomy, physiology, and assessment.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19151265" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : The right ventricle in cardiac surgery, a perioperative perspective: II. Pathophysiology, clinical importance, and management.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28329100" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Long-term cardiovascular changes following creation of arteriovenous fistula in patients with end stage renal disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24875795" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Right heart dysfunction in heart failure with preserved ejection fraction.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25391518" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Right ventricular function in heart failure with preserved ejection fraction: a community-based study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7897128" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Preserved right ventricular ejection fraction predicts exercise capacity and survival in advanced heart failure.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23811750" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Outcome prediction by quantitative right ventricular function assessment in 575 subjects evaluated for pulmonary hypertension.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23965488" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : The prevalence and prognostic significance of right ventricular systolic dysfunction in nonischemic dilated cardiomyopathy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22908015" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Pulmonary hypertension due to left heart disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31120821" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Heart Failure With Preserved Ejection Fraction In Perspective.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35139159" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Heart failure with preserved ejection fraction in patients with normal natriuretic peptide levels is associated with increased morbidity and mortality.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30544228" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Deterioration in right ventricular structure and function over time in patients with heart failure and preserved ejection fraction.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30586767" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : 2018 AHA/ACC Guideline for the Management of Adults With Congenital Heart Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29246897" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Hemodynamics of Fontan failure: The role of pulmonary vascular disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28284370" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Frequency and Associated Clinical Features of Functional Tricuspid Regurgitation in Patients With Chronic Atrial Fibrillation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31637441" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Arrhythmogenic right ventricular cardiomyopathy: evaluation of the current diagnostic criteria and differential diagnosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28081831" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : The Relationship Between the Right Ventricle and its Load in Pulmonary Hypertension.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22131357" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Pulmonary capillary wedge pressure augments right ventricular pulsatile loading.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19215833" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Importance of venous congestion for worsening of renal function in advanced decompensated heart failure.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19215832" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Increased central venous pressure is associated with impaired renal function and mortality in a broad spectrum of patients with cardiovascular disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20152246" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Effect of right ventricular function and venous congestion on cardiorenal interactions during the treatment of decompensated heart failure.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20606118" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Potential effects of aggressive decongestion during the treatment of decompensated heart failure on renal function and survival.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26621644" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Eligibility and Disqualification Recommendations for Competitive Athletes With Cardiovascular Abnormalities: Task Force 3: Hypertrophic Cardiomyopathy, Arrhythmogenic Right Ventricular Cardiomyopathy and Other Cardiomyopathies, and Myocarditis: A Scientific Statement From the American Heart Association and American College of Cardiology.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23741058" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22281246" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Effects of vasodilation in heart failure with preserved or reduced ejection fraction implications of distinct pathophysiologies on response to therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18617068" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Sodium nitroprusside for advanced low-output heart failure.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9743167" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : The short-term effects of digoxin in patients with right ventricular dysfunction from pulmonary hypertension.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27543702" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Digoxin therapy for cor pulmonale: A systematic review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28716832" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Mechanical Circulatory Support Devices for Acute Right Ventricular Failure.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11153735" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Independent and additive prognostic value of right ventricular systolic function and pulmonary artery pressure in patients with chronic heart failure.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
